Dr. Scott M. Rocklage was president and CEO of Nycomed Salutar from 1990 to 1994.
He was a managing partner at the 5AM Ventures office in Boston, Massachusetts. Prior to his role as managing partner, he was a venture partner at 5AM Ventures. From 1992 to 1994, he held three roles at Nycomed Interventional: CEO, president, and chairman.
He was president of Cubist Pharmaceuticals from July 1994 to March 2001. From March 2000 to December 2004, he also served as executive chairman at Cubist Pharmaceuticals. In March 2006, Rocklage began serving as a Director at Pulmatrix.
He worked at Pulmatrix for 11 years at Milkana Therapeutics and Semprus BioSciences Corp, he was Executive Chairman. From August 2014 to March 2015, he was on the Board of Directors of Achaogen. Rocklage was president and CEO at Amersham Health. Read more: Scott Rocklage | LinkedIn
Dr. Rocklage was the CEO of EPIRUS Biopharmaceuticals, Inc. from May 2016 to July 2016. As of July 2014, he was director at EPIRUS Biopharmaceuticals, Inc. until July 2016. He was co-president at Illypsa. At Illypsa, he was also executive chairman.
At Cidara Theraupetics, he was the Chairman of the Board. Rocklage is Board Chairman at Rennovia, Inc. He is a Board Member at Kinestral. Dr. Rocklage is on the Board of Associates at Whitehead Institute. He is director at MDS Proteomics, Inc.
Rocklage completed his undergraduate education at the University of California at Berkley, where he studied chemistry. Also, he got his PhD in Chemistry at the Massachusetts Institute of Technology. At MIT, he did research in the lab of Richard R. Schrock. Richard R. Schrock won the Noble Prize in Chemistry in 2005.
Dr. Scott Rocklage has more than 30 years of experience in health management. He had many jobs in R&D at Salutar and Catalytica Pharmaceuticals.
Due to his success in accomplishing his strategic leadership responsibilities, three U.S. New Drug Applications were approved by the Food and Drug Administration: Omniscan, Telescan, and Cubicin. It is uncertain if Dr. Rocklage could have invented or co-invented more than 30 US patents. Over 100 of his journals have been evaluated by fellow research specialists.
Learn more about Scott Rocklage: